META-ANALYSIS OF EPA AND DHA OMEGA-3 FATTY ACIDS AND CORONARY HEART DISEASE
Researchers included 18 randomized controlled trials (RCTs) and 16 prospective cohort studies into their analysis. The results from the RCTs showed a 6% reduction (not statistically significant) in coronary heart disease (CHD) patients using EPA and DHA. The prospective studies showed a statistically significant 18% reduction in coronary heart disease among participants. Subgroup analysis from the RCTs showed that individuals at higher risk for CHD, such as those with elevated triglycerides and elevated LDL cholesterol, benefitted most from the omega-3 fatty acids, especially at dosages above 1 gram per day.
The conclusions of the meta-analysis support the American College of Cardiology and American Heart Association Task Force’s recommended addition of EPA and DHA omega-3 fatty acids to dietary patterns to support heart health and prevent coronary heart disease.